BioWorld

July 7, 2006

MGI Sells Dacogen Rights Ex-North America To Cilag

Two months after receiving FDA approval for Dacogen to treat myelodysplastic syndromes, MGI Pharma Inc. licensed rights to the drug outside North America to Cilag GmbH. (BioWorld Today) Read More

Alnylam's Amended Merck Deal Worth Up To $120M In Payments

Tethers, Combination Therapy Suggest T-Cell Use In Cancer

Valera Seeking Approval For Annual Implant To Fight CPP

Ambrx's Series C Adds $52M To Advance Lead Candidates

Clinic Roundup

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for July 31, 2026.

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors

BioWorld Science

Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...

Jingxin discloses new muscarinic and sigma receptor agonists

BioWorld Science

Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...

Silhouette illustration of DNA gene editing

Death in Chinese gene-editing trial exposes ethical fault lines

BioWorld

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...